The International Prognostic Score (IPS) is the most commonly used risk stratification tool for patients with advanced Hodgkin lymphoma (HL). It incorporates seven clinical parameters independently associated with a poorer outcome: male sex, age, stage IV, hemoglobin level, white blood cell and lymphocyte counts, and albumin level. Since the development of the IPS, there have been significant advances in therapy and supportive care. Recent studies suggest that the IPS is less discriminating due to improved outcomes with ABVD therapy. The aim of the present study was to asses if classic prognostic factors maintain their prognostic meaning at the time of response-adapted treatment based on interim PET scans. We evaluated the prognostic significance of IPS in the 520 advanced stage HL patients enrolled in the PET-guided, HD0801 trial in which PET2-positive patients underwent a more intense treatment with an early stem-cell transplantation after 2 cycles of ABVD. We observed that in these patients, the IPS completely loses its prognostic value together with all the single parameters that contribute to the IPS. Furthermore, neutrophils, monocytes, lymphocytes, and the ratio among them also no longer had any predictive value. We believe that the substantial improvement in survival outcomes in PET2-positive patients treated with early autologous transplantation could explain the complete disappearance of the residual prognostic significance of the IPS.

The classic prognostic factors in advanced Hodgkin’s lymphoma patients are losing their meaning at the time of Pet-guided treatments / Bari, A.; Marcheselli, R.; Sacchi, S.; Re, A.; Pagani, C.; Tucci, A.; Botto, B.; Vitolo, U.; Molinari, A. L.; Puccini, B.; Pulsoni, A.; Santoro, A.; Tani, M.; Nassi, L.; Meli, E.; Pavone, V.; Bonfichi, M.; Evangelista, A.; Gioia, D.; Levis, A.; Zinzani, P.. - In: ANNALS OF HEMATOLOGY. - ISSN 0939-5555. - 99:2(2020), pp. 277-282. [10.1007/s00277-019-03893-7]

The classic prognostic factors in advanced Hodgkin’s lymphoma patients are losing their meaning at the time of Pet-guided treatments

Bari A.
Writing – Original Draft Preparation
;
Marcheselli R.
Writing – Original Draft Preparation
;
Sacchi S.
Writing – Review & Editing
;
2020-01-01

Abstract

The International Prognostic Score (IPS) is the most commonly used risk stratification tool for patients with advanced Hodgkin lymphoma (HL). It incorporates seven clinical parameters independently associated with a poorer outcome: male sex, age, stage IV, hemoglobin level, white blood cell and lymphocyte counts, and albumin level. Since the development of the IPS, there have been significant advances in therapy and supportive care. Recent studies suggest that the IPS is less discriminating due to improved outcomes with ABVD therapy. The aim of the present study was to asses if classic prognostic factors maintain their prognostic meaning at the time of response-adapted treatment based on interim PET scans. We evaluated the prognostic significance of IPS in the 520 advanced stage HL patients enrolled in the PET-guided, HD0801 trial in which PET2-positive patients underwent a more intense treatment with an early stem-cell transplantation after 2 cycles of ABVD. We observed that in these patients, the IPS completely loses its prognostic value together with all the single parameters that contribute to the IPS. Furthermore, neutrophils, monocytes, lymphocytes, and the ratio among them also no longer had any predictive value. We believe that the substantial improvement in survival outcomes in PET2-positive patients treated with early autologous transplantation could explain the complete disappearance of the residual prognostic significance of the IPS.
23-dic-2019
99
2
277
282
The classic prognostic factors in advanced Hodgkin’s lymphoma patients are losing their meaning at the time of Pet-guided treatments / Bari, A.; Marcheselli, R.; Sacchi, S.; Re, A.; Pagani, C.; Tucci, A.; Botto, B.; Vitolo, U.; Molinari, A. L.; Puccini, B.; Pulsoni, A.; Santoro, A.; Tani, M.; Nassi, L.; Meli, E.; Pavone, V.; Bonfichi, M.; Evangelista, A.; Gioia, D.; Levis, A.; Zinzani, P.. - In: ANNALS OF HEMATOLOGY. - ISSN 0939-5555. - 99:2(2020), pp. 277-282. [10.1007/s00277-019-03893-7]
Bari, A.; Marcheselli, R.; Sacchi, S.; Re, A.; Pagani, C.; Tucci, A.; Botto, B.; Vitolo, U.; Molinari, A. L.; Puccini, B.; Pulsoni, A.; Santoro, A.; Tani, M.; Nassi, L.; Meli, E.; Pavone, V.; Bonfichi, M.; Evangelista, A.; Gioia, D.; Levis, A.; Zinzani, P.
File in questo prodotto:
File Dimensione Formato  
47.pdf

Open access

Descrizione: articolo
Tipologia: Versione pubblicata dall'editore
Dimensione 196.31 kB
Formato Adobe PDF
196.31 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1203344
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 6
social impact